A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Study ID
- NCT07073417
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Obesity
- Weight Management
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- XW003 injection — DRUGSubcutaneous injection
- semaglutide injection — DRUGSubcutaneous injection
Study Details
The aim of the study is to compare the efficacy and safety of XW003 injection versus semaglutide injection in Chinese adults with obesity
Key Dates
- Start date
- Jul 28, 2025
- Status verified
- Jul 2025
- Primary completion
- Feb 27, 2027
- Completion
- Aug 23, 2027
Study Design
- Enrollment
- 163 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: XW003once weekly
- Active Comparator: semaglutideonce weekly
Primary Outcome Measure
Percentage change in body weight relative to baseline [ Time Frame: week 48 ]
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss TreatmentPHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia